These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 4154088)

  • 21. Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation.
    Pachnio A; Dietrich S; Klapper W; Humpe A; Schwake M; Sedlacek R; Gramatzki M; Beck C
    Bone Marrow Transplant; 2006 Jul; 38(2):157-67. PubMed ID: 16820783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction of GvH splenomegaly in mice by antilymphocyte serum (ALS): correlation of the effect with immunosuppressive potency of ALS.
    Mazuran R; Volić B; Silobrcić V
    Z Immunitatsforsch Exp Klin Immunol; 1974 Sep; 147(4):378-83. PubMed ID: 4157053
    [No Abstract]   [Full Text] [Related]  

  • 23. [Emergency problems of the graft vs host reaction (literature survey)].
    Shevelev AS
    Probl Gematol Pereliv Krovi; 1976 Apr; 21(4):35-41. PubMed ID: 16257
    [No Abstract]   [Full Text] [Related]  

  • 24. [Antilymphocyte serum as an immunosuppressant].
    Wiig JN
    Tidsskr Nor Laegeforen; 1973 Mar; 93(9):574-8. PubMed ID: 4148532
    [No Abstract]   [Full Text] [Related]  

  • 25. Marrow transplantation for the treatment of acute leukemia using HL-A-identical siblings.
    Buckner CD; Clift RA; Fefer A; Lerner KG; Neiman PE; Storb R; Thomas ED
    Transplant Proc; 1974 Dec; 6(4):365-6. PubMed ID: 4612892
    [No Abstract]   [Full Text] [Related]  

  • 26. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
    Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of antilymphocyte sera on bone marrow allograft rejection.
    Riches AC; Thomas DB
    Exp Hematol; 1975 Jun; 3(3):169-80. PubMed ID: 1098919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparation of xenogeneic antibodies eliminating lymphocytes from human bone marrow selectively.
    Wulff JC; Anderson M; Held H; Müller-Hermelink HK; Schlaak M; Müller-Ruchholtz W
    Transplant Proc; 1981 Mar; 13(1 Pt 1):230-3. PubMed ID: 7022829
    [No Abstract]   [Full Text] [Related]  

  • 30. Anti-CD4 IgG2a monoclonal antibody treatment prevents the expansion of T cells in the spleen during murine graft-vs-host disease.
    Noort WA; Benner R; Savelkoul HF
    Transplant Proc; 1995 Feb; 27(1):384-6. PubMed ID: 7879030
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunopathology of mouse hepatitis virus type 3mii. effect of immunosuppression in resistant mice.
    Dupuy JM; Levey-Leblond E; Le Prevost C
    J Immunol; 1975 Jan; 114(1 Pt 1):226-30. PubMed ID: 234497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone-marrow transplantation in France, 1958-1973.
    Mathé G; Schwarzenberg L
    Transplant Proc; 1974 Dec; 6(4):335-43. PubMed ID: 4155150
    [No Abstract]   [Full Text] [Related]  

  • 33. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease.
    Ushiyama C; Hirano T; Miyajima H; Okumura K; Ovary Z; Hashimoto H
    J Immunol; 1995 Mar; 154(6):2687-96. PubMed ID: 7876541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed against T cells or their subsets. I. Evidence for the induction of a state of tolerance based on suppression.
    Knulst AC; Tibbe GJ; Noort WA; Bril-Bazuin C; Benner R; Savelkoul HF
    Bone Marrow Transplant; 1994 Mar; 13(3):293-301. PubMed ID: 8199571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antilymphocytic antibodies and marrow transplantation. VI. Absence of immunosuppression in vivo after injection of monoclonal antibodies blocking graft-versus-host reactions and humoral antibody formation in vitro.
    Thierfelder S; Hoffmann-Fezer G; Rodt H; Doxiadis I; Eulitz M; Kummer U
    Transplantation; 1983 Mar; 35(3):249-54. PubMed ID: 6340277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The double barrier in bone marrow transplantation.
    van Bekkum DW
    Semin Hematol; 1974 Jul; 11(3):325-40. PubMed ID: 4151846
    [No Abstract]   [Full Text] [Related]  

  • 37. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of donor bone marrow with OKT3 (PAN-T monoclonal antibody) for prophylaxis of graft-vs.-host disease (GvHD) in histocompatible allogeneic bone marrow transplantation (BMT): a pilot study.
    Filipovich AH; McGlave P; Ramsay NK; Goldstein G; Kersey JH
    J Clin Immunol; 1982 Jul; 2(3 Suppl):154S-157S. PubMed ID: 6752174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone marrow transplantation across the major histocompatibility barrier in specific-pathogen-free mice: effects of intact versus T cell-depleted bone marrow on the expression of anti-host reaction in the recipient spleens.
    Muto M; Sado T; Aizawa S; Kamisaku H; Kubo E
    J Immunol; 1981 Dec; 127(6):2421-5. PubMed ID: 6457876
    [No Abstract]   [Full Text] [Related]  

  • 40. [Letter: Lichen eruptions after allogenic bone marrow graft].
    Saurat JH; Gluckman E; Bussel A; Didier-Jean L
    Nouv Presse Med; 1975 Mar; 4(10):745 (1). PubMed ID: 236539
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.